The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.
Junzo Hamanishi
No relevant relationships to disclose
Masaki Mandai
No relevant relationships to disclose
Takafumi Ikeda
No relevant relationships to disclose
Manabu Minami
No relevant relationships to disclose
Atsushi Kawaguchi
No relevant relationships to disclose
Noriomi Matsumura
No relevant relationships to disclose
Kaoru Abiko
No relevant relationships to disclose
Tsukasa Baba
No relevant relationships to disclose
Ken Yamaguchi
No relevant relationships to disclose
Akihiko Ueda
No relevant relationships to disclose
Masashi Kanai
No relevant relationships to disclose
Yukiko Mori
No relevant relationships to disclose
Shigemi Matsumoto
No relevant relationships to disclose
Toshinori Murayama
No relevant relationships to disclose
Shunsuke Chikuma
No relevant relationships to disclose
Satoshi Morita
No relevant relationships to disclose
Masayuki Yokode
No relevant relationships to disclose
Akira Shimizu
No relevant relationships to disclose
Tasuku Honjo
Research Funding - Ono Pharmaceutical
Ikuo Konishi
No relevant relationships to disclose